MedPath

Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM

Phase 4
Not yet recruiting
Conditions
Neurologic Disorder
Interventions
Registration Number
NCT06382467
Lead Sponsor
Chung-Ang University Gwangmyeong Hospital
Brief Summary

This study aims to compare total intravenous anesthetic agents: combined remimazolam and propofol vs. propofol monotherapy. The comparison parameters are intraoperative hypotension, patient's involuntary movement, neurophysiological monitoring quality, onset time, recovery time, and postoperative rescue anti-emetics requirements.

Detailed Description

This study hypothesizes that the combination regimen of remimazolam and propofol as total intravenous anesthesia in neurosurgical procedures requiring neurophysiological monitoring can reduce the incidence of hypotension compared to propofol monotherapy while providing comparable levels of neurophysiological monitoring and surgical conditions. With this hypothesis, the study aims to compare the frequency, severity, and duration of hypotension, frequency of patient movement, and appropriateness of neurophysiological monitoring between the combination therapy of remimazolam and propofol and propofol monotherapy in total intravenous anesthesia.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
56
Inclusion Criteria
  • Patients aged 19 and above with planned neurosurgical procedures requiring neurophysiological monitoring, classified as American Society of Anesthesiologists (ASA) physical status classification 1, 2, or 3 in the United States.
Read More
Exclusion Criteria
  1. Patients who refuse to participate in the study.
  2. Patients who are pregnant or lactating.
  3. Patients with hypersensitivity to the investigational drugs or to soy, peanuts, or Dextran 40.
  4. Patients with acute narrow-angle glaucoma.
  5. Patients with alcohol or drug dependence.
  6. Patients with hepatic impairment classified as Child-Pugh class C.
  7. Patients with lactose intolerance.
  8. Patients requiring emergency surgery.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Combination groupRemimazolam besylate + propofol MCTCombination regimen (remimazolam plus propofol)
Propofol groupPropofol MCTPropofol monotherapy
Primary Outcome Measures
NameTimeMethod
Incidence of intraoperative hypotensionoperation day - postoperative 1 day

mean arterial pressure \< 65mmHg

Secondary Outcome Measures
NameTimeMethod
Amount and number of inotropic agentsoperation day - postoperative 1 day

intraoperative inotropics amount (phenylephrine(mcg), ephedrine(mg), norepinephrine(mcg), dopamine(mg))

Incidence of participants' intraoperative involuntary movementoperation day - postoperative 1 day

number of patients involuntary movement during operation (ex. no movement:0 , 3 times of movement: 3)

scores of neurophysiologic monitoring qualityoperation day - postoperative 1 day

0-5 scale of neurophysiologic monitoring quality, scored by neurophysiologic monitoring technologist (poor: 0, good: 5)

onset time of study drugsoperation day - postoperative 1 day

time from administration of study drugs(remimazolam+propofol or propofol) to Bispectral index value \< 60

The administration number of rescue anti-emetic agentsoperation day - postoperative 3 day

postoperative rescue anti-emetic agents (ramosetron, palonosetron, metoclopramide) requirements

Time-weighted average of intraoperative hypotensionoperation day - postoperative 1 day

(depth of hypotension in millimeters of mercury below a MAP of 65mmHg × time in minutes spent below a MAP of 65mmHg)÷total duration of operation in minutes

recovery time of study drugs (remimazolam+propofol or propofol)operation day - postoperative 1 day

time from discontinuation of study drugs(remimazolam+propofol or propofol) to Bispectral index value \> 60

© Copyright 2025. All Rights Reserved by MedPath